ClinicalTrials.gg
Enrolling by invitationNCT07490717HOPEUpdated Jun 18, 2026

Developing and Testing Innovative Care Pathways for Screening and Treatment of OUD/PTSD in Jails

An interventional study of Cognitive Processing Therapy (CPT) and Written Exposure Therapy (WET) in Post-traumatic Stress Disorder (PTSD), Post-traumatic Stress Symptoms and Opioid Use Disorder (OUD), sponsored by University of Arkansas. Enrolling by invitation at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by University of Arkansas · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
338
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States — 340 open to participants now, 403 under way, 18 of them phase 3. Stress Disorders, Post-Traumatic · United States.

Planned enrollment
112th of 1,491
338 · median 65
Started
2026
with 96 others
No phase
1,012 of 1,664
234 open now
Primary completion
2029-04
later than 336 of 402 live
Registered
1,603rd of 1,664
by date

Among the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, this one is the 112th largest by planned enrollment of the 1,491 interventional ones that give a count, is one of 97 that started in 2026, is one of 1,012 with no phase, reaches primary completion later than 336 of the 402 other live ones, and was the 1,603rd registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

340 of the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States are open now. Recruiting first, the newest first:

335 more — sign in →

All 340 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, or all of them as a file.
02

Study summary

Opioid overdose is the leading cause of death among people recently released from incarceration. Recent evidence also shows a rise in stimulant use among justice-involved populations, as well as growing rates of concurrent opioid and stimulant use. Yet, while there is growing research on opioid use disorder (OUD), stimulant use disorder (STUD), and substance use treatment in jails and prisons, studies find that few people who are referred to community substance use treatment actually initiate treatment after release. But, emerging research suggests that therapy for posttraumatic stress disorder (PTSD), a common and deleterious OUD and STUD comorbidity, could profoundly increase the likelihood of engagement with substance use treatment; however, this has not been tested in jails, and acceptable, appropriate, and feasible ways to identify and link people with probable PTSD and OUD/STUD in this setting to treatment are required to be able to examine this possibility. Therefore, this 4-year R33 aims to 1) describe engagement in and examine the implementation outcomes of an innovative approach to identifying and referring people with probable PTSD and OUD/STUD to needed treatment services and 2) the effectiveness and implementation outcomes of two competing models of subsequent trauma-focused therapy initiation timing (i.e., immediate initiation of therapy vs initiation upon community reentry) among people who demonstrate need for OUD/STUD services and who accept referral. To address Aim 1, the investigators will assess the implementation context for and subsequently implement a screening, brief intervention, and referral to treatment model that was adapted to identify and address the substance use and mental health needs of adults with probable PTSD and OUD/STUD in the jail setting (SBIRT-J) in the Pulaski County Regional Detention Facility; the investigators will describe engagement in and examine the implementation outcomes of the SBIRT-J model via a summative evaluation guided by the Consolidated Framework for Implementation Research. Specifically, there will be a survey and interview jail stakeholders (e.g., jail leadership, officers) to understand perceptions of the acceptability, appropriateness, and feasibility of the SBIRT-J model as well as SBIRT-J implementation determinants (i.e., barriers and facilitators), and use administrative data to understand the degree to which SBIRT-J is adopted during active enrollment in the R33 Aim 2 research trial and sustained in the 6 months after enrollment end. Fidelity to the SBIRT-J model will also be monitored and reported. To address Aim 2, the investigators will conduct a patient-randomized Hybrid type I implementation-effectiveness trial in which adults who are identified as having probable PTSD and OUD/STUD through the SBIRT-J model and who consent to participate in the trial are randomly assigned to either immediate initiation of therapy for PTSD in jail or initiation of PTSD therapy upon release. The primary effectiveness outcome will be post-release substance use treatment initiation by 6-months post-release from jail; secondary and exploratory outcomes will include substance use treatment readiness and retention, OUD/STUD severity, PTSD symptoms, victimization, overdose, and additional drug use. Participants in the effectiveness portion of the trial (N = 338; \~50% female) will be enrolled from the largest jail in Arkansas. Jail stakeholders will also be enrolled to provide implementation-related data. The overall goal is to translate research to practice to increase the provision of high-quality care for justice-involved persons with probable PTSD and OUD/STUD. Indeed, this study will be the first trial of a treatment for PTSD in jails as a method for improving OUD/STUD outcomes, providing foundational information on PTSD as a novel intervention target for meeting the needs of a particularly vulnerable population and providing the implementation data to inform rapid scale-up, if effective.

03

Conditions studied

  • Post-traumatic Stress Disorder (PTSD)
  • Post-traumatic Stress Symptoms
  • Opioid Use Disorder (OUD)
  • Stimulant Use Disorder
  • Stimulant Use & Co-occuring Opioid Use Disorders
  • Co-occurring Mental and Substance Use Disorders
  • Medications for Opioid Use Disorder

Keywords

  • Post-Traumatic Stress Disorder
  • Trauma
  • Substance Use Disorders
  • Opioid Use Disorder
  • Stimulant Use Disorder
  • SBIRT
  • Screening
  • Brief Intervention
  • Referral to Treatment
  • Trauma-Focused Therapy
  • Cognitive Processing Therapy
  • Cognitive Processing Therapy for Criminal Justice Setting
  • Written Exposure Therapy
  • Criminal Justice
  • Incarceration
  • Detention
  • Jail
  • Implementation
  • Implementation Evaluation
  • Acceptability
  • Appropriateness
  • Effectiveness
  • Evidence-Based Intervention
  • Individual Therapy
  • Stakeholders
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria for all participants:

  • 18 years of age or older
  • Able to understand and speak English
  • Able to give

Inclusion criteria for key stakeholders participating in Aim 1 (additional requirements):

  • All items listed in "Inclusion criteria for all participants"
  • Invited by the PI to participate, due to specific role within the project site

Inclusion criteria for people incarcerated at the study site completing assessments in Aim 2 (additional requirements):

  • All items listed in "Inclusion criteria for all participants"
  • Incarcerated at the study site
  • Screened positive for probable PTSD and OUD/STUD as part of the SBIRT-J process
  • Have an expected duration of incarceration that is compatible with receiving trauma-focused treatment and completing assessments within the remaining timeline of the study

Exclusion criteria for people incarcerated at the study site to enroll in the Hybrid trial in Aim 2 (additional requirements):

  • Unwilling to consent to randomization
  • Unable to provide locator information for post-release assessments
  • Currently experiencing psychiatric symptoms that would preclude participation in CPT or WET (e.g., severe behavioral dysregulation, severe psychotic symptoms)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
338 participants (estimated)

Study arms

  • Experimental
    Intervention Arm (Jail-Initiated PTSD Therapy)

    Following participation in SBIRT-J, individuals who screen positive for both PTSD and OUD/STUD will be invited to participate in the trial. Participants who are randomized to this condition will be referred to begin PTSD therapy as soon as possible, while still in jail. The delivery schedule can be variable to meet participants' needs and preferences. PTSD therapy will be continued post-release if a participant in this condition is released from jail prior to completion (i.e., in cases of earlier-than-expected release) as well as continued if the participant returns to jail while treatment remains ongoing.

    Other: Cognitive Processing Therapy (CPT) · Other: Written Exposure Therapy (WET)

  • Active comparator
    Control Arm (Community-Initiated PTSD Therapy)

    Following participation in SBIRT-J, individuals who screen positive for both PTSD and OUD/STUD will be invited to participate in the trial. Participants who are randomized to this condition will be scheduled to begin PTSD Therapy in the community upon release from jail. The delivery schedule for each community-initiated PTSD Therapy can also be variable to meet participants' needs and preferences. This arm is considered the control arm because it is the arm most consistent with usual care in the jail setting (although a somewhat enhanced usual care condition because direct referral to PTSD Therapy is not made or paid for as standard practice-referral to mental health treatment, more generally, is what would be more typical). As in the Jail-Initiated arm, treatment will continue if the participant returns to jail while treatment remains ongoing.

    Other: Cognitive Processing Therapy (CPT) · Other: Written Exposure Therapy (WET)

Interventions

  • OtherCognitive Processing Therapy (CPT)

    Cognitive Processing Therapy (CPT) is an evidence-based therapy for PTSD that helps people understand how trauma has impacted their life and learn balanced ways to think about the trauma. Participants who choose to pursue CPT will complete worksheets and talk about them with a counselor. CPT will be offered individually; in-person, televideo, and/or phone visits will be acceptable. CPT

  • OtherWritten Exposure Therapy (WET)

    Written Exposure Therapy (WET) is an evidence-based therapy for PTSD that helps people face memories of trauma so they become less upsetting over time, which can helps people feel more in control of their emotions and reactions. Participants who choose to pursue WET will write about the traumatic event and then talk with a counselor. WET will be offered individually; in-person, televideo, and/or phone visits will be acceptable.

06

What researchers measure

Primary outcomes

  1. A2 - Substance Use Treatment Initiation

    Substance use treatment initiation (binary; presence vs absence) will be assessed via participant self-report and verified via medical chart review when possible.

    Time frame: Through study completion, approximately 1 year

Secondary outcomes

  1. A1 - SBIRT-J Acceptability per the Acceptability of Intervention Measure (AIM)

    The extent to which SBIRT-J is perceived as satisfactory by stakeholders. Mean scores on the AIM range from 1-5, with higher scores indicating greater intervention acceptability.

    Time frame: Immediately following the conclusion of Aim 2 enrollment (one-time survey)

  2. A1 - SBIRT-J Appropriateness per the Intervention Appropriateness Measure (IAM)

    The extent to which SBIRT-J is perceived by stakeholders as relevant to and compatible with the setting and population. Mean scores on the IAM range from 1-5, with higher scores indicating greater intervention appropriateness.

    Time frame: Immediately following the conclusion of Aim 2 enrollment (one-time survey)

  3. A1 - SBIRT-J Reach

    The ratio of people who complete SBIRT-J to the number who are booked in the PCRDF during the study period.

    Time frame: Immediately following the conclusion of Aim 2 enrollment

  4. A1 - SBIRT-J Feasibility per the Feasibility of Intervention Measure (FIM)

    The extent to which SBIRT-J is perceived by jail stakeholders as useable. Mean scores on the FIM range from 1-5, with higher scores indicating greater intervention feasibility.

    Time frame: Immediately following the conclusion of Aim 2 enrollment (one-time survey)

  5. A2 - Retention in Substance Use Treatment

    Retention in substance use treatment once initiated will be assessed via participant self-report and verified via medical chart review when possible.

    Time frame: Through study completion, approximately 1 year

  6. A2 - Opioid Use Disorder Severity

    Opioid use disorder (OUD) severity will be assessed via a DSM-5 checklist of OUD diagnostic criteria; this checklist has a maximum score of 11, with higher scores indicating more severe symptoms and scores of ≥2 indicating symptoms likely to meet criteria for OUD. Scores will be examined as both dichotomous (presence vs. absence) and continuous (total number of symptoms).

    Time frame: Through study completion, approximately 1 year

  7. A2 - Stimulant Use Disorder Severity

    Stimulant use disorder (STUD) severity will be assessed via a DSM-5 checklist of STUD diagnostic criteria; this checklist has a maximum score of 11, with higher scores indicating more severe symptoms and scores of ≥2 indicating symptoms likely to meet criteria for STUD. Scores will be examined as both dichotomous (presence vs. absence) and continuous (total number of symptoms).

    Time frame: Through study completion, approximately 1 year

  8. A2 - Opioid Use

    Opioid use will be assessed via participant self-report on the 30-Day Timeline Follow Back Interview and will be examined as both a binary variable and a frequency count representing number of days of use.

    Time frame: Through study completion, approximately 1 year

  9. A2 - Stimulant Use

    Stimulant use will be assessed via participant self-report on the 30-Day Timeline Follow Back Interview. The total number of days of stimulant use will be calculated and examined as a frequency count.

    Time frame: Through study completion, approximately 1 year

  10. A2 - Overall Drug Use Frequency

    Assessed by the Timeline Follow Back Interview. Will be examined as a frequency count (number of days used in the previous 30 days).

    Time frame: Through study completion, approximately 1 year

  11. A2 - Post-Traumatic Stress Disorder (PTSD) Symptom Severity

    Per the PTSD Checklist for DSM-5. Will be a continuous score of 0-80, where lower scores indicate lower PTSD symptoms and thus a better treatment outcome.

    Time frame: Through study completion, approximately 1 year

  12. A2 - Drug-Related Crime

    Assessed via the Criminal and Legal Activities Form. Will primarily be defined as 1) new arrests for drug charges and 2) new convictions for drug charges and will be examined as both a binary variable (presence or absence of any drug-related crime) and frequency counts (number of new drug charges or convictions).

    Time frame: 12 months post-baseline

  13. A2 - Depressive Symptoms

    Assessed via the Patient Health Questionnaire-8. Depressive symptoms will be a continuous score of 0-24 where lower scores indicate lower symptom levels and thus a better treatment outcome.

    Time frame: Immediately and until 12 months post-baseline

  14. A2 - Perceived Appropriateness of SBIRT-J

    Will be assessed with the Intervention Appropriateness Measure.

    Time frame: Immediately (baseline-only)

  15. A2 - Perceived Acceptability of SBIRT-J

    Will be assessed with the Acceptability of Intervention Measure.

    Time frame: Immediately (baseline-only)

  16. A2 - Perceived Appropriateness of Cognitive Processing Therapy (CPT)

    Will be assessed with the Intervention Appropriateness Measure.

    Time frame: Immediately (baseline-only)

  17. A2 - Perceived Acceptability of Cognitive Processing Therapy (CPT)

    Will be assessed with the Acceptability of Intervention Measure.

    Time frame: Immediately (baseline-only)

  18. A2 - Perceived Appropriateness of Written Exposure Therapy (WET)

    Will be assessed with the Intervention Appropriateness Measure.

    Time frame: Immediately (baseline-only)

  19. A2 - Perceived Acceptability of Written Exposure Therapy (WET)

    Will be assessed with the Acceptability of Intervention Measure.

    Time frame: Immediately (baseline-only)

07

Study locations

2 sites
  • Pulaski County Regional Detention Facility
    Little Rock, Arkansas 72204, United States
  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
08

References and documents

Individual participant data

Plan to share: Yes — Information in the research records will be released to requesters, in compliance with NIH's requirements for data sharing. Final research data for this project will also be made as available as possible while safeguarding the privacy of participants and protecting all confidential and proprietary data. This will include depositing data into a shared repository.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Indefinitely, as requested/following the publication of primary manuscripts.

Access criteria: As aforementioned, information in the research records will be released to requesters, in compliance with NIH's requirements for data sharing. Final research data for this project will be made as available as possible while safeguarding the privacy of participants and protecting all confidential and proprietary data. This will include depositing data into a shared repository. Distribution of data to specific requesting entities will be approved by the IRB in accordance with protection of human subject and HIPAA guidelines following the publication of primary manuscripts. Any shared final data sets will be stripped of personal and/or direct identifiers prior to the release of data sharing and protections will be put in place to prevent persons with any unusual characteristics from being identified.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Apr 2029, 38 months after the start.

Of 1,066 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 38 months is close to that.

Counting every sponsor, half of 1,094 studies reached it within 35 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2026
First posted
Mar 24, 2026
StartActual
Jan 20, 2026
Primary completionEst.
Apr 1, 2029
CompletionEst.
Aug 31, 2029
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07490717
Responsible party
Sponsor
First posted
Mar 24, 2026
Start date
Jan 20, 2026
Primary completion
Apr 1, 2029 (estimated)
Completion
Aug 31, 2029 (estimated)
Last update
Jun 18, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion